In March 2025, the company declared new options for just a immediate-to-purchaser offering of its Wegovy weight loss drug. The company recognized a different pharmacy, identified as NovoCare, which might cost buyers $499 per month for access to the drug, less than 50 % the cost of the drug through other pharmaceutical distribution networks.[53]Novo